Acadia Healthcare Lowers Outlook Despite Solid Q3 Revenue Growth and Strong Admissions Momentum
Third-Quarter Revenue Up, But Profitability Under Pressure
Acadia Healthcare’s third-quarter results tell a nuanced story: revenue climbed 4.4% year-over-year to $851.6 million, with same-facility admissions up 3.3%, reflecting accelerating momentum from targeted referral initiatives. However, these gains came alongside ongoing challenges that have forced the company to trim its full-year financial outlook for 2025.
While same-facility revenue increased by 3.7% and same-facility patient days rose by 1.3%, persistent headwinds—most notably lower acute care Medicaid volumes and tighter payor scrutiny—meant patient day growth lagged expectations. Net income attributable to Acadia came in at $36.2 million for the quarter ($0.40 per diluted share), notably down from $0.74 per share in the prior year. Adjusted EBITDA also declined to $173 million, from $194.3 million the previous year, largely due to volume softness, startup costs on new beds, and higher insurance and professional expenses.
Guidance Revised Amid Persistent Challenges
Acadia’s updated guidance reflects the reality of today’s tougher operating environment. Revenue expectations were reduced to $3.28–$3.30 billion (down from $3.30–$3.35 billion previously). The company is now targeting $650–$660 million in adjusted EBITDA (from $675–$700 million) and $2.35–$2.45 adjusted earnings per share (from $2.45–$2.65). Guidance also factors in increased professional liability expenses and uncertain Medicaid reimbursements—highlighted by a potential $22 million in supplemental payments not yet included due to regulatory timing uncertainty.
| Metric | Q3 2025 Actual | Q3 2024 Actual | % Change |
|---|---|---|---|
| Revenue ($ millions) | 851.6 | 815.6 | 4.4% |
| Net Income ($ millions) | 36.2 | 68.1 | -46.8% |
| Adjusted EBITDA ($ millions) | 173.0 | 194.3 | -11.0% |
| Same-Facility Admissions | 51,966 | 50,286 | 3.3% |
| Same-Facility Revenue Per Patient Day ($) | 1,020 | 997 | 2.3% |
Expanding Bed Capacity Remains a Strategic Priority
Despite financial headwinds, Acadia is maintaining a steady expansion of its bed footprint, adding 429 new beds in the third quarter and 908 for the year to date. Much of this expansion comes via joint ventures with major health systems—key moves that strengthen the company’s reach. In parallel, three new comprehensive treatment centers brought the company’s total to 177 centers, treating over 74,000 patients daily.
Management has committed to reducing 2026 capital expenditures by at least $300 million versus 2025 levels. This shift toward disciplined capital deployment aims to improve free cash flow and sharpen the focus on markets with the strongest growth potential.
Service Line Performance Shows Shifting Mix
| Service Line | Q3 2025 Revenue ($M) | % Change vs Q3 2024 |
|---|---|---|
| Acute Inpatient Psychiatric Facilities | 471.5 | 7.2% |
| Specialty Treatment Facilities | 148.1 | -4.9% |
| Comprehensive Treatment Centers | 144.5 | 7.7% |
| Residential Treatment Centers | 87.5 | 1.8% |
Optimizing Portfolio and Enhancing Efficiency
Acadia is acting to bolster efficiency by shifting resources toward its highest-performing facilities and market segments. Notably, labor turnover improved for a sixth consecutive quarter and base wage growth is stabilizing. The company’s investment in real-time quality dashboards helps ensure consistency of care, which management says is a differentiator as payors and regulators increasingly prioritize measurable outcomes.
Leadership changes are underway as well. CFO Todd Young joined in late October, and COO Dr. Nasser Khan will transition to an advisory role through year-end as the company initiates a search for his successor. Management’s near-term focus is on stabilizing volume, increasing admissions, and maintaining operational discipline during a period of evolving macro and reimbursement challenges.
Cash Flow and Balance Sheet: Prioritizing Flexibility
As of September 30, Acadia reported $118.7 million in cash and equivalents, and access to $786.7 million in liquidity via its credit facility. For the nine months ended September 2025, operating cash flow was $218.2 million, down from $13 million in the prior year due to higher non-cash charges and timing factors, with continued investment in bed expansion and network growth. Management is aiming for a return to positive free cash flow in 2026.
Key Takeaways for Investors
- Acadia is balancing top-line momentum and expanded treatment capacity against near-term margin compression and ongoing operating headwinds.
- Reduced guidance reflects the persistent impact of payor, volume, and expense challenges.
- Management’s decisive steps to optimize its portfolio and invest in growth are expected to drive future efficiency and position Acadia favorably when operating conditions improve.
As the largest pure-play behavioral health operator in the U.S., Acadia’s path forward will be closely tied to how it navigates reimbursement risk, manages expansion costs, and leverages its strong footprint. Investors should keep a close eye on regulatory updates, capital allocation discipline, and early results from recent bed additions and referral initiatives in the quarters ahead.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI